FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
Inhibitory targeting of the CD40L-CD40 system is a promising therapeutic option in the field of organ transplantation and is also attractive in the treatment of autoimmune diseases. After early complex results with neutralizing CD40L antibodies, it turned out that lack of Fcγ receptor (FcγR)-binding...
Main Authors: | Isabell Lang, Olena Zaitseva, Harald Wajant |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/21/12869 |
Similar Items
-
Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking
by: Luyan Liu, et al.
Published: (2022-07-01) -
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism
by: Nienke Hesen, et al.
Published: (2024-12-01) -
CD40–CD40L in Neurological Disease
by: Heather D. Ots, et al.
Published: (2022-04-01) -
CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism
by: Johannes Nelke, et al.
Published: (2020-01-01) -
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer
by: Kodchakorn Mahasongkram, et al.
Published: (2023-12-01)